In an unprecedented move, biopharmaceutical company Hoth Therapeutics announced on Wednesday that it plans to buy $1M worth of BTC, sparking market discussions globally. The company’s Board of Directors approved the abovementioned purchase, primarily in an effort to strengthen the firm’s treasury reserve. This announcement has further gained significant traction as the flagship crypto continues to witness soaring institutional interest post-U.S. elections.
Hoth Therapeutics Announce Bitcoin As Treasury Reserve Asset.
According to an official press release dated November 20, Hoth Therapeutics’ Board of Directors approved the purchase of $1M worth of the crypto as the firm’s treasury reserve asset. Notably, Hoth Therapeutics CEO, Robb Kine, stated, “As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset.”
Kine takes the stage to further add that “With recent approval of Bitcoin ETFs and increasing activity from institutional investors, it is a strong addition to our treasury strategy. We believe its inflation-resistant characteristics may make it a reliable asset as a functional store of value.”
Overall, this announcement echoed notable optimism surrounding the largest crypto by market cap, underscoring rising market demand.
The post Just-in: Hoth Therapeutics Board Approves $1M Bitcoin Buying Plan appeared first on CoinGape.
